Quixotic Hope for PeopleSoft Springs Eternal

 
 
By Lisa Vaas  |  Posted 2004-11-09 Email Print this article Print
 
 
 
 
 
 
 

Opinion: Just because Oracle says it will walk away from its bid if it doesn't get 50 percent of shares tendered doesn't mean it's ready to concede the fight—quite the contrary.

Yes, OK, OK, OK, its true. An Oracle lawyer did, in fact, tell the judge in the Delaware anti-poison-pill trial that Oracle would walk away from its 18-month-old, bitterly fought PeopleSoft bid if shareholders dont tender a majority of outstanding shares by Nov. 19. In a letter to the court, Michael Carroll said Oracle would give up its fight to invalidate both the poison pill and the special customer-protection program that PeopleSoft has been using to fend off the takeover, should it fail to garner the shareholder backing it needs. That backing is essential in Oracles quest to launch a proxy battle in the spring, during which the company would attempt to take over PeopleSofts board, install sympathetic directors and vote down the poison pill and customer-assurance plan.
I know there are lots of people who would love to see Oracle fail in its takeover bid. The resistance is completely understandable. Larry Ellison is a tough, arrogant, insert-unpublishable-word-here, and that toughness filters down to every level of his company, whether it be Oracles infamous sales reps or its top-level executives.
The culture gap between the two companies couldnt be wider. As experts often point out, the grueling integration of the two companies following a successful takeover would make this 18-month-old legal saga look like a walk in the park in comparison. But dont let fear and dread cloud your perceptions of reality. What Carroll wrote to Judge Strine is completely in line with what Oracle has been asserting since it made its "best and last" offer of $24 per share. As mergers and acquisitions experts point out, it only makes sense for Oracle to give up on the efforts to dismantle the anti-takeover provisions if it cant get the backing it needs to win the proxy battle.
"Theyve made this Nov. 19 date sort of a pre-referendum on the deal," said Bill Lawlor, an attorney with Dechert LLP, in Philadelphia. "Its not very dramatic for them to say theyd walk away from the litigation if they dont get 50 percent of the shares. Theyd be a loser anyway, and they wouldnt win in next springs proxy contest." The purpose of providing the referendum now is simply to demonstrate to the judge, before he delivers his opinion, that the anti-takeover provisions really do stand between Oracles bid and the shareholders, Lawlor told me. If Oracle cant win over the shareholders, the existence of the poison pill becomes academic. Whats relevant now is whether PeopleSoft shareholders will in fact tender their shares. As of Oracles most recent news release, at the end of October, 20,191,181 shares had been tendered. According to PeopleSoft, that represents 5.5 percent of shares. Next Page: Nobody tenders shares early.



 
 
 
 
Lisa Vaas is News Editor/Operations for eWEEK.com and also serves as editor of the Database topic center. Since 1995, she has also been a Webcast news show anchorperson and a reporter covering the IT industry. She has focused on customer relationship management technology, IT salaries and careers, effects of the H1-B visa on the technology workforce, wireless technology, security, and, most recently, databases and the technologies that touch upon them. Her articles have appeared in eWEEK's print edition, on eWEEK.com, and in the startup IT magazine PC Connection. Prior to becoming a journalist, Vaas experienced an array of eye-opening careers, including driving a cab in Boston, photographing cranky babies in shopping malls, selling cameras, typography and computer training. She stopped a hair short of finishing an M.A. in English at the University of Massachusetts in Boston. She earned a B.S. in Communications from Emerson College. She runs two open-mic reading series in Boston and currently keeps bees in her home in Mashpee, Mass.
 
 
 
 
 
 
 

Submit a Comment

Loading Comments...
 
Manage your Newsletters: Login   Register My Newsletters























 
 
 
 
 
 
 
 
 
 
 
Thanks for your registration, follow us on our social networks to keep up-to-date
Rocket Fuel